Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
SpectRx, Inc. Elects New Directors
April 11th, 2007
SpectRx, Inc. (OTCBB: SPRX) announced the election of new members to the company's board of directors. The company's board of directors elected Ronald W. Hart, Ph.D. and Michael C. James as directors, effective immediately. President and Chief Operating Officer Mark L. Faupel, Ph.D. was elected a director, effective upon the planned April 20, 2007 resignation from the board of William "Bill" D. Arthur, III. "We welcome the new directors to the board and believe that they bring a wealth of talent and experience that will greatly benefit the company as we complete our FDA pivotal clinical trial and bring our non-invasive cervical cancer detection...
Source: Medical Patent Law Weekly (2007-04-11)
|
